Mostrar el registro sencillo del ítem

Artículo

dc.creatorJimenez, Davides
dc.creatorAgusti, Alvares
dc.creatorTabernero, Evaes
dc.creatorJara-Palomares, Luises
dc.creatorHernando, Ascensiones
dc.creatorRuiz-Artacho, Pedroes
dc.creatorOtero Candelera, Remedioses
dc.date.accessioned2022-12-07T15:40:08Z
dc.date.available2022-12-07T15:40:08Z
dc.date.issued2021
dc.identifier.citationJimenez, D., Agusti, A., Tabernero, E., Jara-Palomares, L., Hernando, A., Ruiz-Artacho, P. y Otero Candelera, R. (2021). Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation A Randomized Clinical Trial. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 326 (13), 1277-1285. https://doi.org/10.1001/jama.2021.14846.
dc.identifier.issn0098-7484es
dc.identifier.issn1538-3598es
dc.identifier.urihttps://hdl.handle.net/11441/140218
dc.description.abstractOBJECTIVE To compare usual care plus an active strategy for diagnosing PE with usual care alone in patients hospitalized for COPD exacerbation. DESIGN, SETTING, AND PARTICIPANTS Randomized clinical trial conducted across 18 hospitals in Spain. A total of 746 patients were randomized from September 2014 to July 2020 (final follow-up was November 2020). INTERVENTIONS Usual care plus an active strategy for diagnosing PE (D-dimer testing and, if positive, computed tomography pulmonary angiogram) (n = 370) vs usual care (n = 367). MAIN OUTCOMES AND MEASURES The primary outcome was a composite of nonfatal symptomatic venous thromboembolism (VTE), readmission for COPD, or death within 90 days after randomization. There were 4 secondary outcomes, including nonfatal new or recurrent VTE, readmission for COPD, and death from any cause within 90 days. Adverse events were also collected. RESULTS Among the 746 patients who were randomized, 737 (98.8%) completed the trial (mean age, 70 years; 195 [26%] women). The primary outcome occurred in 110 patients (29.7%) in the intervention group and 107 patients (29.2%) in the control group (absolute risk difference, 0.5% [95% CI, −6.2% to 7.3%]; relative risk, 1.02 [95% CI, 0.82-1.28]; P = .86). Nonfatal new or recurrent VTE was not significantly different in the 2 groups (0.5% vs 2.5%; risk difference, −2.0% [95% CI, −4.3% to 0.1%]). By day 90, a total of 94 patients (25.4%) in the intervention group and 84 (22.9%) in the control group had been readmitted for exacerbation of COPD (risk difference, 2.5% [95% CI, −3.9% to 8.9%]). Death from any cause occurred in 23 patients (6.2%) in the intervention group and 29 (7.9%) in the control group (risk difference, −1.7% [95% CI, −5.7% to 2.3%]). Major bleeding occurred in 3 patients (0.8%) in the intervention group and 3 patients (0.8%) in the control group (risk difference, 0% [95% CI, −1.9% to 1.8%]; P = .99). CONCLUSIONS AND RELEVANCE Among patients hospitalized for an exacerbation of COPD, the addition of an active strategy for the diagnosis of PE to usual care, compared with usual care alone, did not significantly improve a composite health outcome. The study may not have had adequate power to assess individual components of the composite outcome. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT02238639es
dc.formatapplication/pdfes
dc.format.extent9 p.es
dc.language.isoenges
dc.publisherAMER MEDICAL ASSOCIATIONes
dc.relation.ispartofJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 326 (13), 1277-1285.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectPulmonary Embolismes
dc.subjectDiagnostic Strategyes
dc.subjectPatients Hospitalizedes
dc.subjectCOPD Exacerbationes
dc.titleEffect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation A Randomized Clinical Triales
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.contributor.affiliationUniversidad de Sevilla. Departamento de Medicinaes
dc.relation.projectIDPI14/ 00400es
dc.relation.publisherversionhttps://jamanetwork.com/journals/jama/fullarticle/2784660es
dc.identifier.doi10.1001/jama.2021.14846es
dc.journaltitleJAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATIONes
dc.publication.volumen326es
dc.publication.issue13es
dc.publication.initialPage1277es
dc.publication.endPage1285es
dc.contributor.funderInstituto de Salud Carlos IIIes

FicherosTamañoFormatoVerDescripción
Effect of a Pulmonary.pdf344.0KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional